AAP
SGMT icon

Arax Advisory Partners’s Sagimet Biosciences SGMT Stock Holding History

Arax Advisory Partners’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$889 Hold
115
– – ﹤0.01% 4947
2026
Q1 		$601 Hold
115
– – ﹤0.01% 3390
2025
Q4 		$681 Hold
115
– – ﹤0.01% 3556
2025
Q3 		$789 Buy
+115
New +$933 ﹤0.01% 3303
2025
Q1 		– Sell
-115
Closed -$518 – 3005
2024
Q4 		$518 Hold
115
– – ﹤0.01% 2321
2024
Q3 		$319 Hold
115
– – ﹤0.01% 2464
2024
Q2 		$394 Buy
+115
New +$528 ﹤0.01% 2358

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Arax Advisory Partners's SGMT Position: Q2 2026 in Review

Arax Advisory Partners held its Sagimet Biosciences (SGMT) position steady in Q2 2026 at 115 shares worth $889. The position accounts for ﹤0.01% of the portfolio, ranked #4947.

Arax Advisory Partners first reported a position in SGMT in Q2 2024 and has held it in 7 quarters since. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Arax Advisory Partners held 115 shares of Sagimet Biosciences worth $889 as of Q2 2026.
  • Arax Advisory Partners left its Sagimet Biosciences share count unchanged in Q2 2026.
  • Sagimet Biosciences made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4947 holding.
  • Arax Advisory Partners first reported a position in Sagimet Biosciences in Q2 2024 and has held it in 7 quarters since.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.